BR0206533A - Composto, composição farmacêutica, e, uso de um composto - Google Patents

Composto, composição farmacêutica, e, uso de um composto

Info

Publication number
BR0206533A
BR0206533A BR0206533-9A BR0206533A BR0206533A BR 0206533 A BR0206533 A BR 0206533A BR 0206533 A BR0206533 A BR 0206533A BR 0206533 A BR0206533 A BR 0206533A
Authority
BR
Brazil
Prior art keywords
compound
group
optionally substituted
pyrrole ring
heteroaryl group
Prior art date
Application number
BR0206533-9A
Other languages
English (en)
Inventor
Takaichi Schimozato
Yoko Shimada
Tomio Kimura
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BR0206533A publication Critical patent/BR0206533A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, E, USO DE UM COMPOSTO". O objetivo da presente invenção é fornecer uma composição para a profilaxia ou tratamento da hepatopatia. [Solução] Uma composição contendo como um ingrediente ativo um composto da fórmula (I), ou um sal, éster ou outro derivado deste farmacologicamente aceitável para a profilaxia ou tratamento da hepatopatia: [em que: A é um anel pirrol; R^ 1^ é um grupo arila ou heteroarila opcionalmente substituído; R^ 2^ é um grupo heteroarila opcionalmente substituido; R^ 3^ representa um grupo da fórmula -X-R^ 4^, em que X é uma ligação simples ou um grupo alquileno, alquenileno ou alquinileno opcionalmente substituído, e R^ 4^ é um grupo cicloalquila substituído, um grupo arila substituído, um grupo heterociclila opcionalmente substituído, um grupo heteroarila opcionalmente substituído, ou -NR^ a^R^ b^, em que cada um de R^ a^ e R^ B^ é um átomo de hidrogênio ou um grupo alquila, alquenila, alquinila, aralquila ou alquilsulfonila; contanto que os ditos substituintes R^ 1^ e R^ 3^ estejam ligados aos dois átomos do dito anel pirrol que são adjacentes ao átomo do anel pirrol ao qual o dito substituinte R^ 2^ está ligado].
BR0206533-9A 2001-01-18 2002-01-17 Composto, composição farmacêutica, e, uso de um composto BR0206533A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001009629 2001-01-18
PCT/JP2002/000290 WO2002057254A1 (fr) 2001-01-18 2002-01-17 Compositions destinees a la prevention et au traitement de l'hepatopathie

Publications (1)

Publication Number Publication Date
BR0206533A true BR0206533A (pt) 2003-12-16

Family

ID=18877075

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206533-9A BR0206533A (pt) 2001-01-18 2002-01-17 Composto, composição farmacêutica, e, uso de um composto

Country Status (7)

Country Link
EP (1) EP1352906A4 (pt)
KR (1) KR20030076612A (pt)
CN (1) CN1525968A (pt)
BR (1) BR0206533A (pt)
CA (1) CA2435141A1 (pt)
MX (1) MXPA03006468A (pt)
WO (1) WO2002057254A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009592A1 (ja) * 2002-07-19 2004-01-29 Sankyo Company, Limited 二環性不飽和３級アミン化合物
US7166634B2 (en) 2004-01-23 2007-01-23 Nereus Pharmaceuticals, Inc. Bis-indole pyrroles useful as antimicrobials agents
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3294616B2 (ja) * 1995-08-10 2002-06-24 メルク エンド カンパニー インコーポレーテッド ２−置換アリールピロール、このような化合物を含む組成物及び使用方法
AU699148B2 (en) * 1995-08-10 1998-11-26 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
EP0859771A4 (en) * 1995-10-31 2000-03-15 Merck & Co Inc SUBSTITUTED PYRIDYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHOD OF USE
EP0912548A1 (en) * 1996-07-11 1999-05-06 Pfizer Inc. Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
AU4395399A (en) * 1998-07-02 2000-01-24 Sankyo Company Limited Five-membered heteroaryl compounds
AU4315100A (en) * 1999-04-28 2000-11-17 Sankyo Company Limited Preventive or inhibitory agents for hepatopathy
IL137365A0 (en) * 1999-07-21 2001-07-24 Sankyo Co Heteroaryl-substituted pyrrole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JP2001181187A (ja) * 1999-12-27 2001-07-03 Sankyo Co Ltd ５員ヘテロアリール化合物を含有する組成物

Also Published As

Publication number Publication date
EP1352906A1 (en) 2003-10-15
CN1525968A (zh) 2004-09-01
MXPA03006468A (es) 2003-09-22
EP1352906A4 (en) 2004-06-16
WO2002057254A1 (fr) 2002-07-25
CA2435141A1 (en) 2002-07-25
KR20030076612A (ko) 2003-09-26

Similar Documents

Publication Publication Date Title
BR0010520A (pt) Novos compostos farmaceuticamente ativos
BR0111754A (pt) Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
BR0014137A (pt) Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica
BR9806413A (pt) Composto e uso do mesmo
BR9908764A (pt) Composto e seus sais farmaceuticamente aceitáveis ou ésteres hidrolisáveis in vivo, uso destes, processo para prepará-los, e, composição farmacêutica
BRPI0517343A (pt) derivados de betulina, preparação destes e uso dos mesmos
BR0206955A (pt) Ligantes de receptores de canabinóides
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
AR042368A1 (es) Un compuesto derivado de purina, su uso, un procedimiento para prepararlo y una composicion farmaceutica que lo comprende
UY27336A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR0010476A (pt) Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais
BR9914451A (pt) Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento
BR0009558A (pt) Composto derivado bicìclico heteroaromático, composição farmacêutica, e, uso de compostos derivados bicìclicos heteroaromáticos
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
BR0306292A (pt) Composto de éster e uso medicinal do mesmo
BRPI0509307A (pt) compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1
BRPI0507944A (pt) composição farmacêutica
AR018634A1 (es) Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos.
ES2163295T3 (es) Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa.
BRPI0817096A8 (pt) Análogo de tiazolidinodiona e composição farmacêutica que o compreende
BRPI0417947A (pt) composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica
BRPI0409241A (pt) compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso
BR0213464A (pt) Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired